Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. MRNA
2. KLAR
3. KEYS
4. PANW
5. HD
6. SPY
7. MRK
8. DVLT
9. NBIS
10. MRCY

Go back to Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist

UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data

September 28, 2016 11:46 AM EDT

(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)

Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.

According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.

... More